Summary Adhesion of cancer cells to vascular endothelium is an important step in haematogenous metastasis of cancer. A human hepatocellular carcinoma cell line, HepG2, strongly adheres to human umbilical vein endothelial cells (HUVECs) through the interaction of Eselectin and its carbohydrate ligand sialyl Lewis X. In this study, we investigated alteration in integrin expression on HepG2 cells, which follows the selectin-mediated initial adhesion of HepG2 cells to HUVECs. Expression of afil integrin was markedly increased when the HepG2 cells adhered to HUVECs. Among the tested cytokines that are known to be produced by endothelial cells, recombinant hepatocyte growth factor (rHGF) could replace the effect of HUVECs, and a similar increase in integrin expression was observed by the addition of 20 ng ml-' rHGF to HepG2. The increment of a2fil integrin expression was significantly inhibited by anti-HGF neutralizing antibody treatment. HepG2 cells expressed a2, a6, f, and 4 integrin subunits, but expression of integrins other than a2fi was not affected by the rHGF treatment.
Haematogenous metastasis of cancer is a complicated process consisting of multiple steps. The attachment of cancer cells to vascular endothelium is possibly initiated by the cell adhesion mediated by E-selectin on endothelial cells and carbohydrate ligands on cancer cells (Hakomori, 1992; Majuri et al, 1992; Dejana et al, 1992; Takada et al, 1991 Takada et al, , 1993 . The only exceptions known are non-epithelial malignant cells, such as melanoma or neuroblastoma and fibrosarcoma, which bind to endothelial cells mainly through VCAM-1. The carbohydrate determinants, sialyl Lewis A and sialyl Lewis X, expressed on cancer cells serve as ligands for E-selectin (Lowe et al, 1990; Phillips et al, 1990; Takada et al, 1991 Takada et al, , 1993 . Sialyl Lewis A is primarily involved in the adhesion of cancers of digestive organs, while sialyl Lewis X is mainly involved in the adhesion of liver, breast, lung and ovary cancer cells to endothelial cells (Majuri et al, 1992; Dejana et al, 1992; Takada et al, 1991 Takada et al, , 1993 .
The selectin-carbohydrate interaction can be regarded as an important factor that facilitates adhesion of cancer cells to Correspondence to: R Kannagi, Laboratory of Experimental Pathology, Research Institute, Aichi Cancer Center, 1-1 Kanokoden, Chikusaku, Nagoya, 464, Japan endothelial cells during the course of haematogenous metastasis (Merwin et al, 1992; Giavazzi et al, 1993) . In vitro experiments indicated that E-selectin expression on endothelial cells is induced by cytokines, such as interleukin 1 (IL-1) and/or tumour necrosis factor alpha (TNFax) (Bevilacqua et al, 1987) , suggesting that this cell adhesion system is heavily involved, especially in cancer metastasis into damaged and/or inflamed tissues. Some cancer cells are known to express IL-1 and other cytokines that activate endothelial cells (Li et al, 1992; Alexandroff et al, 1994; Hayashi et al, 1994) , and these cytokines, through the induction of cell surface E-selectin, would also facilitate the adhesion of cancer cells to endothelial cells. Serum E-selectin levels are known to be elevated in patients with cancers, reflecting the enhanced expression of Eselectin in the vessel walls of these patients (Banks et al, 1993; Ye et al, 1995) . Recent immunohistochemical studies also indicate that small vessels adjacent to cancer nests express E-selectin strongly (Ye et al, 1995) . All these findings suggest the importance of E-selectin-mediated cell adhesion in cancer metastasis.
However, the sequence of events following the initial step of cell adhesion and leading to the extravasation of cancer cells remains largely unknown. Here, we have studied the expression of integrins on cancer cells after the cells underwent the selectin-mediated initial adhesion process to endothelial cells. We also tried to identify the molecular species of affected integrins and cytokines involved in the regulation of their expression.
MATERIALS AND METHODS Cell culture, chemical reagents and antibodies
The human hepatocellular cancer cell line, HepG2 (ATCC, Rockville, MD, USA), was maintained in Dulbecco's modified Eagle medium (DMEM, GIBCO/BRL, Grand Island, NY, USA), supplemented with 10% fetal calf serum (FCS) . Human umbilical vein endothelial cells (HUVECs, Seikagaku Kogyo, Tokyo, Japan) were maintained in Daigo's T medium (Nissui Seiyaku, Tokyo) supplemented with 10% FCS and 2 ng ml-' recombinant bFGF (kindly provided by Takeda Pharmaceutical Osaka, Japan). Purity of HUVECs was ascertained by flow cytometric analysis using anti-factor VIII antibody and was more than 99% throughout the experiments described in this study.
Recombinant human IL-i1 was kindly provided by Otsuka Pharmaceutical (Tokushima, Japan). Human MIP-P, recombinant human IL-8 and human keratinocyte growth factor (KGF) were obtained from Pepro Tech (Rocky Hill, NJ, USA). Recombinant human hepatocyte growth factor (rHGF) was purified from culture medium of CHO cells transfected with plasmid containing the human HGF cDNA (Nakamura et al, 1989 (Takada et al, 1991 (Takada et al, 1991 .
Flow cytometric analysis for cell surface integrin expression To study the change in integrin expression induced by selectinmediated cell adhesion, HepG2 cells were adhered to the monolayer of HUVECs and co-cultured for 24 h at 37°C. To assess the effect of cytokines on integrin expression, HepG2 cells were cultured with 20 ng ml-' rHGF or other cytokines for 24 h at 37°C. Flow cytometric analysis of HepG2 cells was performed using FACScan (Becton Dickinson Immuno-cytometry System, Mountain View, CA, USA) as described previously . The indirect immunofluorescence method was applied for staining of HepG2 cell integrins, using an anti-integrin antibody as the first antibody and a fluorescein isothiocyanate (FITC)-labelled mouse anti-Ig as the second antibody (Cappel, Malvern, PA, USA). Experiments for the inhibition of integrin expression were performed using rabbit antisera raised against human rHGF (Montesano et al, 1991) . Rabbit anti-IL-IJ (kindly supplied by Otsuka Pharmaceutical, Tokushima, Japan) and anti-bFGF antibodies (kindly provided by Takeda Pharmaceutical, Osaka, Japan) served as control antibodies in these experiments. These antibodies were added at 1/50 -1/250 dilution to the mixed culture of HepG2 and HUVECs for 24 h at 37°C before flow cytometric analysis.
Cellular enzyme-linked immunosorbent assay (CELISA) for cell surface integrins Quantitative CELISA for total integrin expression was performed on the monolayer of HepG2 cells that were grown in 96-well plates. After incubation with culture medium containing 20 ng ml-' rHGF for 24 h unless otherwise indicated, the plate was washed twice with PBS and fixed by adding 0.1% glutaraldehyde for I h at room temperature. The plate was washed three times with PBS and unbound surfaces were blocked with 5% bovine serum albumin (BSA) in PBS overnight at 4°C. After washing twice with PBS, 50 gl of the primary antibodies was added to the wells and incubated for 1 h at room temperature. After washing three times with PBS, a 1:100 dilution of peroxidase-conjugated goat anti-mouse IgG (Zymed Laboratories, San Francisco, CA, USA) was added as the secondary antibody and incubated for 1 h at room temperature. The excess enzyme conjugates were then removed by washing three times with PBS, and 50 gl of the substrate, O-phenylenediamine in citrate buffer, containing 0.015% hydrogen peroxide, was added to each well for 10-15 min at room temperature. The colour reaction was stopped with 2M sulphuric acid (50 gl per well), and absorbance was measured using a microplate reader (Tosoh, Tokyo) at 492 nm.
Cell attachment assay to ECM molecules
The 24-well plates were coated with 5 gg ml collagen I (Seikagaku Kogo, Tokyo) or 20 ,ug ml' laminin (Takara Shuzo, Otsu, Japan) at 4'C overnight (Staatz et al, 1989; Carter et al, 1990) , and the wells were washed three times with PBS. Unbound surfaces were blocked with 0.5% BSA in PBS for I h, and again the wells were washed three times with PBS. HepG2 cells (5 x 105), after the preincubation with 20 ng ml-' rHGF for 24 h, were added in a volume of 500 gl per well to each substrate-coated well and then incubated for 30 min at 37°C. The wells were then washed three times with PBS to remove unattached cells. The number of attached cells was counted directly under a microscope. cells. HepG2 cells were cultured in DMEM containing rHGF (20 ng ml-'), KGF (100 ng ml-'), IL-153 (2 ng ml-'), bFGF (2 ng ml-'), HB-EGF (10 ng ml-'), TGF-(5 ng ml-'), IL-8 (10 ng ml-') or MIP-1 (100 ng ml-') for 24 h, and expression of the oap, integrin was assessed by CELISA using anti-CD49b (Albini et al, 1987) .
Chemoinvasion assay

RESULTS
Initial adhesion step of HepG2 cells to endothelial cells
HepG2 cells strongly adhered to rIL-l-activated HUVECs ( Figure  1 ). The contribution of cell adhesion molecules to the adhesion of HepG2 cells was evaluated using specific monoclonal antibodies. When the rIL-In-activated HUVECs were pretreated with antibodies directed to E-selectin, ICAM-1 or VCAM-1, adhesion was significantly inhibited only by the treatment with anti-E-selectin antibody ( Figure IA) . The results demonstrated that the expression of a2[l integrin on HepG2 cells was significantly increased by co-cultivation with HUVECs ( Figure 2A) . Next, HepG2 cells were treated with various cytokines that are reported to be produced by endothelial cells, to determine which cytokine produced by HUVECs was responsible for the observed up-regulation of c2, integrin expression. The results of CELISA are shown in Figure 3 . Among the tested cytokines, rHGF had the strongest up-regulating effect on the ac20[ integrin expression.
Some other cytokines, such as bFGF or IL-1i, enhanced the expression, but only weakly. No significant change was noted by the treatment with IL-8, MIP-1 [3 or KGF.
The enhancing effect of rHGF was confirmed by flow cytometric analysis. After HepG2 cells were cultured in the presence of 20 ng ml-1 rHGF for 24 h, the expression of cc,[, integrin on HepG2 cells was up-regulated to the same level as that obtained by the co-cultivation with HUVECs ( Figure 2B ). Figure 4A ). Figure 4B shows the time course of rHGF action on integrin expression, indicating that an increase in integrin expression was already detectable after 1 h, with an apparent maximum being observed after 24 h. Co-cultivation with HUVECs +anti-IL-1 ,B
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In experiment 1, the net increase in mean fluorescence intensity of a2-integrin (CD49b) on HepG2 cells that had been treated with 20 ng ml-' (see Figure 2B ), compared with that of non-treated HepG2 cells, was taken as 100%. In experiment 2, the net increase in mean fluorescence intensity of a2-integrin on HepG2 cells that had been co-cultured with HUVECs (see Figure  2A ), was taken as 100%. Enhancement of adhesion to collagen and of transmigratory activity
The attachment assay to collagen I and laminin of HepG2 cells was carried out to investigate whether the increased expression of aj, integrin really affects the adhesive behaviour of the HepG2 cells to the putative ECM ligands for the integrin. As shown in Figure 6A , HepG2 cells cultured in the presence of rHGF showed an increased binding activity to collagen, the putative ligand for the a2j, integrin. On the other hand, the attachment to laminin showed no significant change. This result is in line with the finding that the expression of the a6 integrin subunit on HepG2 cells showed no change upon stimulation with rHGF, since laminin is the putative ligand for the a6c61 integrin.
The adhesion of HGF-treated HepG2 cells to collagen was nearly completely inhibited by the treatment with anti-a2 or anti-P1
antibodies, but not with anti-a6 antibody ( Figure 6B ). This result indicates that the augmentation in the adhesion was caused by the activation of afi-integrin by rHGF.
We also performed chemoinvasion experiments to evaluate the effect of the co-cultivation with HUVECs or of the addition of rHGF on the transmigratory activity of the HepG2 cells (Figure 7 ). In these experiments, the lower wells of the 24-well plates contained collagen, and the cancer cells migrating through Matrigel and appearing at the lower membrane surface were evaluated. HepG2 cells co-cultured with HUVECs had a higher invading activity than non-treated HepG2 cells ( Figure 7A ). The same level of increment in the transmigratory activity was attained when HepG2 cells were stimulated with rHGF ( Figure 7B ). 
Effect of anti-HGF antibody on integrin expression of HepG2 cells
An inhibition experiment exploying neutralizing antisera against rHGF was performed to determine whether the enhancement of the integrin expression by HUVECs is mediated by HGF produced by HUVECs. This rabbit antisera preparation completely inhibited the up-regulation induced by rHGF. On the other hand, HUVECinduced enhancement of the a2o21 integrin expression was inhibited by about 50%.
This result indicates that at least 50% of the enhancing effect on the integrin expression, which was exerted by the co-cultivation with HUVECs, is mediated by HGF produced by HUVECs. The mechanisms involved in the other 50% remain unclear. One possible explanation for the latter would be the additional action of other cytokines that have a weak enhancing effect, such as bFGF and/or IL-1,B. However, the addition of rabbit anti-IL-l or antibFGF antibody did not abolish the enhancement of the integrin expression (Table 1) . Another possibility would be that the neutralization of rHGF is difficult when the stimulative effect is conveyed by direct physical contact between HUVECs and HepG2 cells.
DISCUSSION
Exudation of leucocytes to endothelial cells is known to be initiated by the cell adhesion mediated by selectins and carbohydrate ligands (Stoolman, 1989; Springer and Lasky, 1991) . This is followed by the second step of cell adhesion that is mediated by integrins and corresponding molecules of the immunoglobulin superfamily, such as ICAM-1 and VCAM-1, with this step assumed to induce the exudation of leucocytes into extravascular tissues (Stoolman, 1989; Springer and Lasky, 1991) . LFA-1, the ligand for ICAM-1, and VLA-4, the ligand for VCAM-1, are abundantly expressed on leucocytes. In contrast to this, expression of LFA-1 or VLA-4 is relatively rare in epithelial cancer cells, while a2, a3, a6, Bi and 4 integrin subunits are commonly expressed on most cancer cells (Weinel et al, 1992; Albelda, 1993; Volpes et al, 1993; our (Kuijpers et al, 1992; Tanaka et al, 1993) . In the case of HepG2 cells, MIP-1, and IL-8 were devoid of any detectable effect on integrin expression. British Journal of Cancer (1997) Hepatocyte growth factor (HGF) was first identified as a potent stimulator of hepatocyte growth and DNA synthesis . Following its purification and sequencing, its identity with scatter factor was established (Nakamura et al, 1989) . It is well established that HGF is produced by endothelial cells as well as fibroblasts and macrophages (Noji et al, 1990; . HGF produced by the endothelial cells was even suggested to affect the adhesive activity of lymphocytes at the vessel wall (Adams et al, 1994) . Various inflammatory cytokines, including IL-1,B3, are known to stimulate the production of HGF . In this context, it is notable that the expression of E-selectin, which plays an important role as a ligand for carbohydrate antigens in the adhesion to cancer cells, is also induced by inflammatory cytokines, such as IL-i1 , (Bevilacqua et al, 1989) . Taken together, it is surmised that production of HGF is enhanced at the vascular endothelium that expresses E-selectin. The possibility that cancer cells, such as HepG2, eventually produce HGF in response to some stimuli exerted by activated endothelial cells remains.
In line with the increase in the a251 integrin expression, the attachment of HepG2 cells to collagen was enhanced by the addition of rHUF. We also carried out a chemoinvasion assay using an experimental system that resembles the in vivo condition of cancer cell transmigration at the vessel wall. When collagen was used as the chemoattractant, the invasion of HepG2 cells was greatly enhanced by co-cultivation with HUVEC monolayers. A similar level of enhancement in transmigratory activity was observed by the addition of rHGF to HepG2 cells. These findings suggest that HGF facilitates exudation of HepG2 cells into extravascular tissues. HGF is known to enhance cell mobility (Tajima et al, 1992; Shibamoto et al, 1992) , and a part of this activity would be related to its effect on integrin expression as described in this study.
Recent evidence suggests that HGF increases the motility and invasiveness of cancer cells both under in vitro and in vivo conditions (Tajima et al, 1992; Shibamoto et al, 1992; Yoshinaga et al, 1993; Yamashita et al, 1994) . In this study, we propose that HGF would also be involved in the haematogenous metastasis of cancer, at the step of adhesion of cancer cells to endothelial cells. HGF has been demonstrated as displaying a variety of biological activities on various target cell types, including epithelial neoplasma (Tajima et al, 1992; Shibamoto et al, 1992; Yoshinaga et al, 1993) . The wide spectrum of targets of HGF corresponds to the expression of its receptor, a tyrosine kinase, first described as the c-met proto-oncogene product. Several investigators reported that amplification of the c-met proto-oncogene may participate in carcinogenesis and progression of gastric cancer (Kuniyasu et al, 1992) , colorectal cancer (Liu et al, 1992) and thyroid cancer (Di Renzo et al, 1992) . This would also imply that the HGF-mediated enhancement of integrin expression would be limited to the cancer cells that express the c-met oncogene product. In our hands, HGF exerted a similar effect on some cancer cells, such as A431 cells, besides HepG2, but had no effect on some other cancer cells. For such cancer cells that do not respond to HGF, other cytokines, such as KGF, heparin-binding EGF (HB-EGF) or amphiregulin, can be considered as candidates for the cytokines that act in the second step of adhesion. These cytokines share characteristics common to HGF in that their main target is epithelial cells and they are produced by endothelial cells and associated with proteoglycanlike structures at the endothelial cell surface. Our preliminary results indicated that HB-EGF had an enhancing effect on integrin expression on some oesophageal and breast cancer cells (T Narita, N Kawakami and R Kannagi, manuscript in preparation). The cell lineage restriction in the action of HGF and other cytokines in the second step of cell adhesion is in contrast to the situation in the first step of adhesion, in which the selectin-mediated adhesion of cancer cells to endothelial cells is commonly observed in a wide range of epithelial cancer cells.
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Abbreviations E-selectin (ELAM-1), endothelial-leucocyte adhesion molecule 1; ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1; LFA-1, lymphocyte function-associated antigen 1; VLA-4, very-late antigen 4; HUVEC, human umbilical vein endothelial cell; IL-1, interleukin 1.
